275 related articles for article (PubMed ID: 24140934)
21. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
[TBL] [Abstract][Full Text] [Related]
22. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
Zhang YJ; Patel D; Nan Y; Fan S
Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
[TBL] [Abstract][Full Text] [Related]
24. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
[TBL] [Abstract][Full Text] [Related]
25. Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells.
Wakao K; Watanabe T; Takadama T; Ui S; Shigemi Z; Kagawa H; Higashi C; Ohga R; Taira T; Fujimuro M
Biochem Biophys Res Commun; 2014 Feb; 444(2):135-40. PubMed ID: 24434142
[TBL] [Abstract][Full Text] [Related]
26. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
Ueno M; Kariya R; Sittithumcharee G; Okada S
Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
[TBL] [Abstract][Full Text] [Related]
28. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
29. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
31. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
34. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
[TBL] [Abstract][Full Text] [Related]
35. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
[TBL] [Abstract][Full Text] [Related]
36. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.
Gopalakrishnan R; Matta H; Chaudhary PM
Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928
[TBL] [Abstract][Full Text] [Related]
37. Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.
Chandrasekharan JA; Huang XM; Hwang AC; Sharma-Walia N
J Virol; 2016 Dec; 90(24):11020-11031. PubMed ID: 27681120
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
[TBL] [Abstract][Full Text] [Related]
40. Effects of ER stress on unfolded protein responses, cell survival, and viral replication in primary effusion lymphoma.
Shigemi Z; Baba Y; Hara N; Matsuhiro J; Kagawa H; Watanabe T; Fujimuro M
Biochem Biophys Res Commun; 2016 Jan; 469(3):565-72. PubMed ID: 26692493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]